VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FTHFaeth Therapeutics, Inc.
$9.04$568M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFTHBalance Sheet

Faeth Therapeutics, Inc. (FTH) Balance Sheet

8Y historyFree accessUpdated daily

Total debt has fallen from $5.0M in 2024Q2 to $145.0K in 2026Q3, yet cash of $14.2M against a $170.2M net loss in 2026Q1 suggests the balance sheet relies on periodic equity raises and offers a thin cash cushion.

Income StatementBalance SheetCash FlowRatios

FTH Balance Sheet

Annual statement

FTH Balance Sheet

Faeth Therapeutics, Inc. (FTH) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets177.84M21.51M41.93M67.25M108.59M148.54M20.08M502K1.28M
Cash & Short-Term Investments174.79M21.18M41.34M65.76M107.12M147.62M16.6M251K653K
Cash Only14.18M8.67M9.99M13.01M17.8M7.16M16.6M251K653K
Short-Term Investments160.62M12.52M31.34M52.75M89.32M140.46M000
Accounts Receivable000000000
Days Sales Outstanding---------
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets3.05M92K120K325K344K374K2.1M0123K
Total Non-Current Assets1.11M1.4M3.43M7.12M9.79M4.68M1.35M715K570K
Property, Plant & Equipment127K1.38M3.38M7.04M9.72M4.64M1.27M268K123K
Fixed Asset Turnover0.00x--------
Goodwill000000000
Intangible Assets000000000
Long-Term Investments000000000
Other Non-Current Assets981K18K48K86K63K39K86K447K447K
Total Assets178.95M22.9M45.36M74.37M118.38M153.22M21.43M1.22M1.85M
Asset Turnover0.00x--------
Asset Growth %1431.35%-49.51%-39.01%-37.17%-22.74%615.07%1660.72%-34.22%-
Total Current Liabilities11.03M4.25M5.45M5.64M9.07M4.89M4.83M21.71M2.66M
Accounts Payable2.99M689K244K1.69M4.47M2.46M3.88M3.45M1.11M
Days Payables Outstanding6.34-161.631.08K903.011.31K6.78K17.25K9.19K
Short-Term Debt145K00000016.05M696K
Deferred Revenue (Current)00000002.08M652K
Other Current Liabilities7.9M1.4M2.01M0000-1.96M207K
Current Ratio16.12x5.06x7.70x11.92x11.98x30.38x4.16x0.02x0.48x
Quick Ratio16.12x5.06x7.70x11.92x11.98x30.38x4.16x0.02x0.48x
Cash Conversion Cycle---------
Total Non-Current Liabilities53K59K1.53M3.84M5.9M1.82M705K48.16M52.67M
Long-Term Debt059K0000567K04.05M
Capital Lease Obligations001.53M3.77M5.9M1.67M86K00
Deferred Tax Liabilities000000000
Other Non-Current Liabilities53K0067K0149K52K48.16M48.62M
Total Liabilities11.09M4.31M6.97M9.48M14.97M6.71M5.54M69.88M55.33M
Total Debt145K1.51M3.85M6.21M8.03M2.35M685K16.05M4.75M
Net Debt-14.04M-7.16M-6.15M-6.8M-9.76M-4.8M-15.91M15.8M4.09M
Debt / Equity0.00x0.08x0.10x0.10x0.08x0.02x0.04x--
Debt / EBITDA-0.00x--------
Net Debt / EBITDA0.06x--------
Interest Coverage-71014.33x-657.91x-334.08x-256.69x-220.86x-53.92x-10.90x-6.42x-38.87x
Total Equity167.86M18.59M38.39M64.89M103.41M146.51M15.89M-68.66M-53.48M
Equity Growth %1608.99%-51.57%-40.85%-37.24%-29.42%821.87%123.15%-28.39%-
Book Value per Share6.5014.7530.5746.4367.36105.7410.39-46.83-36.47
Total Shareholders' Equity167.86M18.59M38.39M64.89M103.41M146.51M15.89M-68.66M-53.48M
Common Stock3K03K3K3K3K02K2K
Retained Earnings-489.78M-283.14M-262.05M-231.9M-197.79M-149.21M-112.41M-92.31M-75.57M
Treasury Stock000000000
Accumulated OCI-153K1K-13K-209K-1M-333K0-2K-314K
Minority Interest000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Thin cash cushion post-2026Q1

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Asset Base Swelled Then Reversed

Based on reported figures, FTH's total assets climbed from $59.8M in 2024Q2 to $205.4M in 2026Q1 before falling back to $178.9M in 2026Q3, a pattern that appears driven by a large cash inflow followed by steady consumption.

The 2026Q1 spike was driven almost entirely by cash rising to $152.3M, which suggests a financing or capital event rather than operating strength. Cash then fell to $14.2M by 2026Q3, indicating that the balance sheet is now far more fragile than the headline asset figure implies. Investors should monitor whether the remaining asset base can sustain operations without further capital.

Current Ratio Masks Thin Cash Cushion

According to reported financial statements, FTH's current ratio of 16.12 in 2026Q3 looks robust, yet cash of $14.2M against a quarterly net loss of $170.2M in 2026Q1 suggests limited buffer against continued burn.

The elevated current ratio largely reflects a small liability base of $11.1M rather than abundant liquid resources, so it overstates true resilience. With operating cash flow negative in every quarter and cash falling from $152.3M to $14.2M within two quarters, the implied runway appears short. This warrants close attention to how quickly remaining cash is being consumed.

Deepening Accumulated Deficit Drives Equity

As reported in balance sheet data, FTH's retained earnings deficit widened from -$247.0M in 2024Q2 to -$489.8M in 2026Q3, while equity still stands at $167.9M due to periodic capital raises.

The accumulated deficit has grown every quarter, indicating persistent losses that have been absorbed by equity financing rather than earnings. Equity of $167.9M is therefore sustained by paid-in capital that appears to be the main source of solvency. The quality of this equity depends on continued access to capital markets, which the reported figures do not guarantee.

Stock Compensation Inflates Equity Base

Based on reported stock-based compensation rising to $12.9M in 2026Q1, a meaningful share of operating cost is settled in equity, which may dilute existing holders and flatter the apparent cash position.

Equity-settled compensation adds to paid-in capital without consuming cash, so a healthy-looking equity figure may partly reflect non-cash awards rather than invested capital. This may indicate dilution that is not visible in the balance sheet totals alone. Investors should assess share count growth alongside the equity figure before treating it as a measure of underlying strength.

Minimal Debt Limits Leverage Risk

According to reported figures, FTH's total debt fell from $5.0M in 2024Q2 to $145.0K in 2026Q3, leaving a debt-to-equity ratio near zero and limiting leverage as a source of balance sheet pressure.

Debt has been run down steadily, which suggests the company is not relying on borrowing to fund its operations. The near-zero leverage removes refinancing risk, though it also means the company depends on equity financing for survival. The balance sheet risk is therefore one of cash exhaustion rather than debt service.

FTH — Frequently Asked Questions

Quick answers to the most common questions about buying FTH stock.

What are the total assets of Faeth Therapeutics, Inc. (FTH)?

As of 2025, Faeth Therapeutics, Inc. (FTH) had total assets of $22.9M including $21.5M in current assets.

How much debt does Faeth Therapeutics, Inc. (FTH) have?

Faeth Therapeutics, Inc. (FTH) carries total debt of $1.5M, offset by $21.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Faeth Therapeutics, Inc.?

Faeth Therapeutics, Inc. (FTH) has total shareholders' equity (book value) of $18.6M ($14.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Faeth Therapeutics, Inc.'s current ratio and liquidity?

Faeth Therapeutics, Inc. (FTH) reported a current ratio of 5.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.